Le Lézard
Classified in: Environment, Health
Subjects: ENI, NTA, ANW, DEI

From Poop to Proof: GEMSTONE Project Aims to Flush Out Source of Marine Fecal Pollution


Highlights

VANCOUVER, BC, March 25, 2024 /CNW/ - Fecal pollution in BC's marine waters can lead to prolonged closures of shellfish harvesting areas and recreational beaches. These are important public health responses, but current surveillance methods can only detect the presence of fecal bacteria in the water, not the source ? human or animal.

A two-year project led by researchers from the University of British Columbia (UBC) and the BC Centre for Disease Control (BCCDC), funded through Genome British Columbia's (Genome BC) GeneSolve Program, is poised to improve how we monitor and identify fecal pollution sources in marine waters.

"We need a better way to identify the source(s) of fecal pollution in marine waters," says Dr. Natalie Prystajecky, a project co-lead from UBC. "Currently, when contamination is detected, harvesting areas are closed quickly. Often, the source of contamination is not known, which means there is no mechanism to prevent the contamination from happening again."

The project, Genomic Ecological Microbial Source Tracking for Oceans Nature and the Environment, or GEMSTONE, will develop new methods using genomic-derived technology to determine the type and origin of fecal contaminations. The research team is working on creating a two-step microbial source tracking test. Step 1 will distinguish between human and non-human contamination. If the contamination is non-human, step 2 will determine what animal is the source. The project will create presentations and training materials to help the industry and Indigenous communities easily learn how to use the new resources.

The BC Shellfish Growers Association and the Malahat Nation are partners on the project. The new test will empower local communities to gain greater control and implement better management options to respond to contamination. The shellfish industry is a vital part of the local economy in the Comox to Deep Bay region, which produces up to 70% of BC's oyster production. Permanently addressing contamination sources will help First Nations remove long term barriers that disproportionately affect their economy, food sources and ceremonial harvesting.

"The real value here is consumer confidence in the industry," says Suzanne Gill, President and CEO of Genome BC. "The precision of these tests will serve as an early warning system so that we can improve the safety and viability of BC's shellfish industry."

A 2016?2017 Norovirus outbreak linked to oysters that affected 400 Canadians and left the shellfish industry dealing with upwards of $9.1 million in losses underscores the public health and economic urgency of this research.

About Genome British Columbia: 
Genome BC is a not-for-profit organization supporting world-class genomics research and innovation to grow globally competitive life sciences sectors and deliver sustainable benefits for British Columbia, Canada and beyond. The organization's initiatives are improving the lives of British Columbians by advancing health care as well as addressing environmental and natural resource challenges. In addition to scientific programming, Genome BC works to integrate genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences among educators, students and the public. genomebc.ca

SOURCE Genome British Columbia


These press releases may also interest you

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...



News published on and distributed by: